CLINICAL_TRIALS
trial_result
· 2021-10-15
Clinical Trial Update: Effect of Efpeglenatide on Cardiovascular Outcomes [Phase 3]
Summary
Phase 3 trial update for efpeglenatide assessing cardiovascular outcomes in type 2 diabetes patients has been terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Sanofi | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: TERMINATED | Results posted: 2021-10-15